Extent of lymph node dissection for adenocarcinoma of the stomach

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Mocellin, Simone ^a   Mcculloch, Peter ^b   Kazi, Hussain ^c   Gama Rodrigues, Joaquin J ^d   Yuan, Yuhong ^e   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Hospital de Clinicas   (Brazil)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; GASTRECTOMY; HUMAN; INTERVENTION STUDY; LYMPH NODE DISSECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; SURGICAL MORTALITY; SURVIVAL ANALYSIS; SYSTEMATIC REVIEW; ADENOCARCINOMA; META ANALYSIS; MORTALITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH NEOPLASMS; SURVIVAL RATE;

ADENOCARCINOMA; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84991210478     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001964.pub4     Document Type: Review

References (53)

1. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. British Journal of Cancer 1999;79:1522-30.
2. Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. British Journal of Surgery 2014;101:23-31.
3. Maeta M, Yamashiro H, Saito H, Katano K, Kondo A, Tsujitani S, et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999;125:325-31.
4. Robertson CS, Chung SC, Woods SD, Griffin SM, Raimes SA, Lau JT, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Annals of Surgery 1994;220:176-82.
5. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. New England Journal of Medicine 2008;359:453-62.
6. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology 2010;11:439-49.
7. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncology 2006;7:309-15.
8. Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. International Journal of Clinical Oncology 2008;13:132-7.
9. Bonenkamp JJ, van De Velde CJH, Sasako M, Hermans J. R2 compared with R1 resection for gastric cancer: morbidity and mortality in a prospective randomised trial. European Journal of Surgery 1992;158:413-8.
10. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, et al. Extended lymph-node dissection for gastric cancer. New England Journal of Medicine 1999;340:908-14.
11. Bunt AMG, Hermans J, Cornelis JH, van de Velde CJH, Sasako M, Hoefsloot FAM, et al. Lymph node retrieval in a randomised trial on Western-type versus Japanese-type surgery in gastric cancer. Journal of Clinical Oncology 1996;14:2289-94.
12. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996;347:995-9.
13. Degiuli M, Sasako M, Ponti A, Italian Gastric Cancer Study Group. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. British Journal of Surgery 2010;97:643-9.
14. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. British Journal of Surgery 1988;75:110-2.
15. Galizia G, Lieto E, De Vita F, Castellano P, Ferraraccio F, Zamboli A, et al. Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis. Surgery 2015;157:285-96.
16. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. Journal of Clinical Oncology 2004;22:2069-77.
17. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M, Szczepanik A. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. American Journal of Surgery 2007;193:10-5.
18. Onate Ocana MF, Aiello Crocofogilio V, Mondragon Sanchez R, Ruiz-Molina JM. Survival benefit of D2 lymphadenectomy in patients with gastric carcinoma. Annals of Surgical Oncology 2000;7:210-7.
19. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. Journal of Clinical Oncology 2004;22:2767-73.
20. Viste A, Svanes K, Jannsen CW, Maartmann Moe H, Soreide O. Prognostic importance of radical lymphadenectomy in curative resections for gastric cancer. European Journal of Surgery 1994;160:497-502.
21. Volpe CM, Driscoll DL, Douglass HO. Outcome of patients with proximal gastric cancer depends upon the extent of resection and the number of resected lymph nodes. Annals of Surgical Oncology 2000;7(2):139-44.
22. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Shia LT, Whang-Peng J. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. British Journal of Surgery 2004;91:283-7.
23. Akagi T, Shiraishi N, Kitano S. Lymph node metastasis of gastric cancer. Cancers 2011;3:2141-59.
24. Allum WH. Optimal surgery for gastric cancer: is more always better?. Recent Results in Cancer Research 2012;196:215-27.
25. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. British Medical Journal 1999;319:1492-5.
26. Arigami T, Uenosono Y, Yanagita S, Nakajo A, Ishigami S, Okumura H, et al. Clinical significance of lymph node micrometastasis in gastric cancer. Annals of Surgical Oncology 2013;20:515-21.
27. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of localized gastric cancer. Journal of Surgical Oncology 2013;107:265-70.
28. Brar SS, Seevaratnam R, Cardoso R, Law C, Helyer L, Coburn N. A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer. Gastric Cancer 2012;15(Suppl 1):S89-99.
29. Cuschieri SA, Hanna GB. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma: let us move on to another era. Annals of Surgery 2014;259:e90.
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315:629-34.
31. El-Sedfy A, Dixon M, Seevaratnam R, Bocicariu A, Cardoso R, Mahar A, et al. Personalized surgery for gastric adenocarcinoma: a meta-analysis of D1 versus D2 lymphadenectomy. Annals of Surgical Oncology 2014;22:1820-7. [DOI: 10.1245/s10434-014-4168-6]
32. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2014;136:E359-86.
33. Giuliani A, Miccini M, Basso L. Extent of lymphadenectomy and perioperative therapies:two open issues in gastric cancer. World Journal of Gastroenterology 2014;20:3889-904.
34. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64:380-2.
35. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009;374:477-90.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327:557-60.
37. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Jansen EP, Boot H, van de Velde CJ, van Sandick J, Cats A, Verheij M. Can adjuvant chemoradiotherapy replace extended lymph node dissection in gastric cancer?. Recent Results in Cancer Research 2012;196:229-40.
39. Jiang L, Yang KH, Guan QL, Zhao P, Chen Y, Tian JH. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta analysis. Journal of Surgical Oncology 2013;107:807-14.
40. Jiang L, Yang KH, Chen Y, Guan QL, Zhao P, Tian JH. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy inpatients with resectable gastric cancer. British Journal of Surgery 2014;101:595-604.
41. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. British Medical Journal 2009;339:b2700.
42. Memon MA, Subramanya MS, Khan S, Hossain MB, Osland E, Memon B. Metaanalysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Annals of Surgery 2011;253:900-11.
43. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
44. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
45. Saka M, Morita S, Fukagawa T, Katai H. Present and future status of gastric cancer surgery. Japanese Journal of Clinical Oncology 2011;41:307-13.
46. Seevaratnam R, Bocicariu A, Cardoso R, Mahar A, Kiss A, Helyer L, et al. A meta analysis of D1 versus D2 lymph node dissection. Gastric Cancer 2012;15(Suppl 1):S60-9.
47. The role of lymphadenectomy in curative surgery for gastric cancer. Soga J, Kobayashi K, Saito J, Fujimaki M, Muto T. World Journal of Surgery 1979;3(6):701-8.
48. StataCorp . Stata Statistical Software: Release 11. College Station, Tx: StataCorp LP, 2009.
49. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. British Medical Journal 2011;343:343:d4002.
50. de Steur WO, Dikken JL, Hartgrink HH. Lymph node dissection in resectable advanced gastric cancer. Digestive Surgery 2013;30:96-103.
51. Verlato G, Giacopuzzi S, Bencivenga M, Morgagni P, De Manzoni G. Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer. World Journal of Gastroenterology 2014;20:12883-91.
52. Yang SH, Zhang YC, Yang KH, Li YP, He XD, Tian JH, et al. An evidence-based medicine review of lymphadenectomy extent for gastric cancer. American Journal of Surgery 2009;197:246-51.
53. Yashiro M, Matsuoka T. Sentinel node navigation surgery for gastric cancer: Overview and perspective. World Journal of Gastrointestinal Surgery 2015;27:1-9.